- Home
- CBIO vs WALD Comparison
CBIO vs WALD Comparison
Compare CBIO & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- WALD
- Stock Information
- Founded
- CBIO 2003
- WALD 1988
- Country
- CBIO United States
- WALD United States
- Employees
- CBIO N/A
- WALD N/A
- Industry
- CBIO
- WALD Package Goods/Cosmetics
- Sector
- CBIO
- WALD Consumer Discretionary
- Exchange
- CBIO Nasdaq
- WALD Nasdaq
- Market Cap
- CBIO 308.0M
- WALD 306.3M
- IPO Year
- CBIO N/A
- WALD 2021
- Fundamental
- Price
- CBIO $14.29
- WALD $1.56
- Analyst Decision
- CBIO Strong Buy
- WALD Strong Buy
- Analyst Count
- CBIO 5
- WALD 5
- Target Price
- CBIO $25.60
- WALD $4.96
- AVG Volume (30 Days)
- CBIO 97.6K
- WALD 526.1K
- Earning Date
- CBIO 07-31-2025
- WALD 11-11-2025
- Dividend Yield
- CBIO N/A
- WALD N/A
- EPS Growth
- CBIO N/A
- WALD N/A
- EPS
- CBIO N/A
- WALD N/A
- Revenue
- CBIO N/A
- WALD $273,868,000.00
- Revenue This Year
- CBIO N/A
- WALD $10.37
- Revenue Next Year
- CBIO N/A
- WALD $14.37
- P/E Ratio
- CBIO N/A
- WALD N/A
- Revenue Growth
- CBIO N/A
- WALD 25.55
- 52 Week Low
- CBIO $10.83
- WALD $1.50
- 52 Week High
- CBIO $21.40
- WALD $4.40
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- WALD 35.98
- Support Level
- CBIO $13.50
- WALD $1.50
- Resistance Level
- CBIO $16.00
- WALD $1.79
- Average True Range (ATR)
- CBIO 0.79
- WALD 0.16
- MACD
- CBIO 0.16
- WALD 0.00
- Stochastic Oscillator
- CBIO 39.68
- WALD 10.00
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.